海南医科大学学报

目的:比较聚乙二醇干扰素与拉米夫定治疗HBeAg阳性慢性乙型肝炎疗效,为临床药物治疗提供参考。方法:HBeAg阳性慢性乙型肝炎患者80例,随机分为观察组与对照组,每组40例,两组均经综合保肝治疗,对照组加用拉米夫定治疗,观察组加用聚乙二醇干扰素治疗,比较治疗前、后两组肝功能指标丙氨酸转氨酶(ALT)、总胆红素(TBIL)、白蛋白(ALB)的水平,以及HBeAg/HBeAb血清转换与HBV DNA转阴情况。结果:两组治疗前ALT、TBIL、ALB水平无明显差异(P均>0.05),治疗后两组各指标都有明显下降(P<0.05),观察组下降幅度明显大于对照组(P均<0.05);治疗后观察组的HBeAg/HBeAb血清转换率(30.0%)与HBV DNA转阴率(80.0%)明显高于对照组(15.0%、40.0%),差异有统计学意义(P均<0.05)。结论:聚乙二醇干扰素治疗HBeAg阳性慢性乙型肝炎能有效改善肝功能状态,同时提高HBeAg/HBeAb血清转换率与HBV DNA转阴率,值得推广应用。

Objective: To observe the pegylated interferon and lamivudine treatment of HBeAg-positive chronic hepatitis B treatment comparison to provide reference for clinical drug treatment.Methods: HBeAg-positive chronic hepatitis B of 80 patients divided into two groups according to admission order level-the treatment group and control group 40 cases.Liver in both groups after combined treatment with lamivudine plus control group,the control group were treated with pegylated interferon therapy.Results: The two groups before treatment liver function(ALT,TBIL,ALB) and other contrast was no significant difference(P>0.05),after treatment,has decreased significantly(P<0.05),but the decline in the treatment group was significantly higher in the control group(P<0.05).After treatment,the treatment group HbeAg / HbeAb seroconversion rate and HBV DNA negative conversion rates were 30.0% and 80.0%,while the control group were 15.0% and 40.0%.Treatment group HbeAg/HbeAb seroconversion rate and HBV DNA negative rate was significantly higher,the difference was significant difference(P<0.05).Conclusion: Compared with interferon,the lamivudine treatment of HBeAg-positive chronic hepatitis B can improve liver function,while increasing HbeAg / HbeAb seroconversion and HBV DNA negative conversion rate,should be widely applied.